Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Stock or Unit Option Plan Expense

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Stock or Unit Option Plan Expense

ANIXA BIOSCIENCES, INC. (ANIX) reported Stock or Unit Option Plan Expense of $4.80 million for the 9-month period ending 2021-07-31, per its 10-Q filed 2021-09-01.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:StockOptionPlanExpense · last filed 2021-09-01

  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for the quarter ending 2021-07-31 was $3.05M, a 205.70% increase year-over-year.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for the quarter ending 2021-04-30 was $880.78K, a 16.54% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for the quarter ending 2021-01-31 was $874.86K, a 9.24% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for the quarter ending 2020-10-31 was $906.41K, a 20.54% increase year-over-year.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for fiscal 2020 was $3.92M, a 10.16% increase from fiscal 2019.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for fiscal 2019 was $3.56M, a 37.72% decline from fiscal 2018.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for fiscal 2018 was $5.72M, a 368.86% increase from fiscal 2017.
  • ANIXA BIOSCIENCES, INC. stock or unit option plan expense for fiscal 2017 was $1.22M, a 39.60% increase from fiscal 2016.
Period endStock or Unit Option Plan Expense 3 monthStock or Unit Option Plan Expense 6 monthStock or Unit Option Plan Expense 9 monthStock or Unit Option Plan Expense 12 monthStock or Unit Option Plan Expense 12 month as first filed
2021-07-31$3.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-09-01
$3.93M
derived: sum of 2 quarters · filed 2021-09-01
$4.80M
10-Q · filed 2021-09-01
$5.71M
derived: sum of 4 quarters · filed 2021-09-01
2021-04-30$880.78K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-06-10
$1.76M
10-Q · filed 2021-06-10
$2.66M
derived: sum of 3 quarters · filed 2021-06-10
$3.66M
derived: sum of 4 quarters · filed 2021-06-10
2021-01-31$874.86K
10-Q · filed 2021-03-11
$1.78M
derived: sum of 2 quarters · filed 2021-03-11
$2.78M
derived: sum of 3 quarters · filed 2021-03-11
$3.83M
derived: sum of 4 quarters · filed 2021-06-10
2020-10-31$906.41K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07
$1.90M
derived: sum of 2 quarters · filed 2021-01-07
$2.96M
derived: sum of 3 quarters · filed 2021-06-10
$3.92M
10-K · filed 2021-01-07
2020-07-31$997.00K
10-Q · filed 2020-09-08
$2.05M
derived: sum of 2 quarters · filed 2021-06-10
$3.02M
10-Q · filed 2021-09-01
$3.77M
derived: sum of 4 quarters · filed 2021-06-10
2020-04-30$1.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-06-10
$2.02M
10-Q · filed 2021-06-10
$2.77M
derived: sum of 3 quarters · filed 2021-06-10
$3.56M
derived: sum of 4 quarters · filed 2021-06-10
2020-01-31$963.88K
10-Q · filed 2021-03-11
$1.72M
derived: sum of 2 quarters · filed 2021-03-11
$2.50M
derived: sum of 3 quarters · filed 2021-03-11
$3.30M
derived: sum of 4 quarters · filed 2021-03-11
2019-10-31$751.97K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07
$1.54M
derived: sum of 2 quarters · filed 2021-01-07
$2.34M
derived: sum of 3 quarters · filed 2021-01-07
$3.56M
10-K · filed 2021-01-07
2019-07-31$784.00K
10-Q · filed 2020-09-08
$1.59M
derived: sum of 2 quarters · filed 2020-09-08
$2.81M
10-Q · filed 2020-09-08
$4.93M
derived: sum of 4 quarters · filed 2020-09-08
2019-04-30$805.10K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-06-09
$2.02M
10-Q · filed 2020-06-09
$4.14M
derived: sum of 3 quarters · filed 2020-06-09
$7.27M
derived: sum of 4 quarters · filed 2020-06-09
2019-01-31$1.22M
10-Q · filed 2020-03-09
$3.34M
derived: sum of 2 quarters · filed 2020-03-09
$6.46M
derived: sum of 3 quarters · filed 2020-03-09
$6.72M
derived: sum of 4 quarters · filed 2020-03-09
2018-10-31$2.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09
$5.25M
derived: sum of 2 quarters · filed 2020-01-09
$5.50M
derived: sum of 3 quarters · filed 2020-01-09
$5.72M
10-K · filed 2020-01-09
2018-07-31$3.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-09-06
$3.38M
derived: sum of 2 quarters · filed 2019-09-06
$3.60M
10-Q · filed 2019-09-06
$3.89M
derived: sum of 4 quarters · filed 2019-09-06
2018-04-30$258.11K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-06-12
$472.53K
10-Q · filed 2019-06-12
$759.23K
derived: sum of 3 quarters · filed 2019-06-12
$1.24M
derived: sum of 4 quarters · filed 2019-06-12
2018-01-31$214.43K
10-Q · filed 2019-03-13
$501.12K
derived: sum of 2 quarters · filed 2019-03-13
$982.24K
derived: sum of 3 quarters · filed 2019-03-13
$1.17M
derived: sum of 4 quarters · filed 2019-03-13
2017-10-31$286.69K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11
$767.81K
derived: sum of 2 quarters · filed 2019-01-11
$959.73K
derived: sum of 3 quarters · filed 2019-01-11
$1.22M
10-K · filed 2019-01-11
$1.22M
10-K · filed 2018-01-09
2017-07-31$481.12K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-09-07
$673.04K
derived: sum of 2 quarters · filed 2018-09-07
$932.77K
10-Q · filed 2018-09-07
$1.24M
derived: sum of 4 quarters · filed 2018-09-07
2017-04-30$191.92K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-06-11
$451.65K
10-Q · filed 2018-06-11
$755.03K
derived: sum of 3 quarters · filed 2018-06-11
$995.47K
derived: sum of 4 quarters · filed 2018-06-11
2017-01-31$259.74K
10-Q · filed 2018-03-09
$563.11K
derived: sum of 2 quarters · filed 2018-03-09
$803.55K
derived: sum of 3 quarters · filed 2018-03-09
$1.02M
derived: sum of 4 quarters · filed 2018-03-09
2016-10-31$303.37K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-09
$543.81K
derived: sum of 2 quarters · filed 2018-01-09
$761.07K
derived: sum of 3 quarters · filed 2018-01-09
$873.56K
10-K · filed 2018-01-09
2016-07-31$240.44K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08
$457.69K
derived: sum of 2 quarters · filed 2017-09-08
$570.19K
10-Q · filed 2017-09-08
$908.20K
derived: sum of 4 quarters · filed 2017-09-08
2016-04-30$217.25K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-26
$329.75K
10-Q · filed 2017-05-26
$667.76K
derived: sum of 3 quarters · filed 2017-05-26
$1.45M
derived: sum of 4 quarters · filed 2017-05-26
2016-01-31$112.50K
10-Q · filed 2017-03-16
$450.50K
derived: sum of 2 quarters · filed 2017-03-16
$1.23M
derived: sum of 3 quarters · filed 2017-03-16
$2.30M
derived: sum of 4 quarters · filed 2017-03-16
2015-10-31$338.01K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-08
$1.12M
derived: sum of 2 quarters · filed 2016-12-08
$2.18M
derived: sum of 3 quarters · filed 2016-12-08
$2.68M
10-K · filed 2016-12-08
2015-07-31$780.59K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-19
$1.85M
derived: sum of 2 quarters · filed 2016-08-19
$2.34M
10-Q · filed 2016-08-19
$3.14M
derived: sum of 4 quarters · filed 2016-08-19
2015-04-30$1.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-20
$1.56M
10-Q · filed 2016-05-20
$2.36M
derived: sum of 3 quarters · filed 2016-05-20
$2.83M
derived: sum of 4 quarters · filed 2016-05-20
2015-01-31$491.78K
10-Q · filed 2016-02-19
$1.29M
derived: sum of 2 quarters · filed 2016-02-19
$1.76M
derived: sum of 3 quarters · filed 2016-02-19
$2.92M
derived: sum of 4 quarters · filed 2016-02-19
2014-10-31$803.21K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23
$1.27M
derived: sum of 2 quarters · filed 2015-12-23
$2.43M
derived: sum of 3 quarters · filed 2015-12-23
$3.15M
10-K · filed 2015-12-23
2014-07-31$469.48K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-18
$1.63M
derived: sum of 2 quarters · filed 2015-08-18
$2.35M
10-Q · filed 2015-08-18
2014-04-30$1.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-22
$1.88M
10-Q · filed 2015-05-22
2014-01-31$720.64K
10-Q · filed 2015-03-09
2012-10-31$615.00K
10-K · filed 2013-01-29
2011-10-31$742.00K
10-K · filed 2013-01-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92